AI is moving inside the device. Who owns the clinical risk?

As AI capabilities integrate deeper into Class II and III medical devices, manufacturers face mounting questions about clinical risk ownership and accountability. The article examines how design and development decisions made years before deployment can create downstream trust and safety issues, and offers guidance for medtech teams to establish clear responsibility frameworks for AI-driven device outputs.